PD-L1 blockade engages tumor-infiltrating lymphocytes to co-express targetable activating and inhibitory receptors

BACKGROUND: The clinical benefit of immunotherapeutic approaches against cancer has been well established although complete responses are only observed in a minority of patients. Combination immunotherapy offers an attractive avenue to develop more effective cancer therapies by improving the efficac...

Descripción completa

Detalles Bibliográficos
Autores principales: Beyrend, Guillaume, van der Gracht, Esmé, Yilmaz, Ayse, van Duikeren, Suzanne, Camps, Marcel, Höllt, Thomas, Vilanova, Anna, van Unen, Vincent, Koning, Frits, de Miranda, Noel F. C. C., Arens, Ramon, Ossendorp, Ferry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6694641/
https://www.ncbi.nlm.nih.gov/pubmed/31412943
http://dx.doi.org/10.1186/s40425-019-0700-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6694641/
https://www.ncbi.nlm.nih.gov/pubmed/31412943
http://dx.doi.org/10.1186/s40425-019-0700-3

Ejemplares similares